NLRP3 is a member of a family of proteins known as inflammasome receptors and is a key component of the NLRP3 inflammasome, which is implicated in a host of diseases characterised by runaway ...

The California-based biopharma is developing cavrotolimod, a spherical TLR9 agonist that is designed to trigger innate and adaptive immune responses by binding to and activating the protein TLR9. In ...

The progress with some newer adjuvanted influenza vaccines is promising. Adjuvants based on toll-like receptor agonists including TLR4 and TLR9 agonists used in pandemic and “universal” influenza ...